{"id":"W2128030263","doi":"10.1016/s0140-6736(12)60771-5","title":"Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":579,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"PCSK9; Ezetimibe; Medicine; Evolocumab; Alirocumab; Placebo; Internal medicine; Statin; Gastroenterology; Population; Familial hypercholesterolemia; Tolerability; Clinical endpoint; Cholesterol; Apolipoprotein B; Endocrinology; Lipoprotein; Randomized controlled trial; Adverse effect; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003541701,0.0005045339,0.002722506,0.0001822305,0.0001107626,0.00004625026,0.0002896758,0.0001317954,0.00001886079],"category_scores_gemma":[0.0003267901,0.0002364501,0.0002194285,0.0004274237,0.00009223168,0.0001459323,0.00005844322,0.0005195392,0.00001494239],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001602962,"about_ca_system_score_gemma":0.0002071638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000960269,"about_ca_topic_score_gemma":0.000122008,"domain_scores_codex":[0.9954588,0.001347316,0.0006456102,0.0005272451,0.00114134,0.0008796516],"domain_scores_gemma":[0.9974591,0.0002730632,0.000278852,0.001376415,0.0001758704,0.0004367123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9551066,0.001663539,0.0117202,0.0001780182,0.0004141577,0.0000206879,0.001662621,0.00006329618,0.003871128,6.849937e-7,0.00007114514,0.02522795],"study_design_scores_gemma":[0.8990542,0.03597683,0.04989477,0.0007910571,0.000231939,0.000020872,0.00004535021,0.00003441425,0.01346056,8.265345e-7,0.0001932411,0.0002959744],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9738511,0.00006083779,0.0002086281,0.0003658693,0.0001573628,0.02515492,0.00005591207,0.00005886464,0.00008647004],"genre_scores_gemma":[0.9949511,0.00001512138,0.0006187915,0.001536616,0.0009365202,0.001725604,0.00004747171,0.00008353688,0.00008520903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05605241,"threshold_uncertainty_score":0.9642156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01989425375777931,"score_gpt":0.3207090111616874,"score_spread":0.3008147574039081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}